catabasis CONNECTION

SPECIAL EDITION NEWSLETTER

How to say edasalonexent:

ē-dah-saloh-*nex*-ent

But we just call it edasa!

An overview of the PolarisDMD trial

We are currently enrolling a Phase 3 clinical trial, PolarisDMD, to study edasalonexent in Duchenne muscular dystrophy. We are enrolling boys ages 4 to 7 (up to 8th birthday), any mutation type, who have not been on steroids for at least 6 months. In PolarisDMD, two boys will receive edasalonexent for each boy who receives placebo, and study drug is provided as a gel capsule, taken 3 times per day with food. Boys may then have the opportunity to receive edasalonexent in our open-label extension, GalaxyDMD. Site visits for this Phase 3 clinical trial are once every 3 months, and travel costs are covered. For more information, please visit **www.clinicaltrials.gov**, or email **DMDtrials@catabasis.com**





Why edasalonexent (CAT-1004)

Edasalonexent inhibits NF-kB, a protein which plays a fundamental role in skeletal and cardiac muscle disease in Duchenne. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasa is being developed as a potential stand-alone therapy and may have the potential to be combined with dystrophin-targeted therapies.

CLINICAL TRIAL RESULTS SEEN TO DATE WITH EDASALONEXENT

We studied edasalonexent in our Phase 2 MoveDMD trial and open-label extension. In this study we saw improvements in muscle function and markers of muscle health compared to an off-treatment control period. We also saw that boys grew similarly to boys who do not have Duchenne and that edasa was well-tolerated without known side effects of steroids.

Stay updated on our progress!

Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php
Follow us @CatabasisPharma.
Ask a question about the trial: DMDtrials@catabasis.com

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.

catabasis

POLARIS DMD